Confronto

Glepaglutide vs. Semax

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

nessun dato

80714-61-0

Peso molecolare

nessun dato

813.92 g/mol

Emivita

nessun dato

0.3 h

Sequenza

nessun dato

Met-Glu-His-Phe-Pro-Gly-Pro

Meccanismo d'azione

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

Semax

Semax is a tetracosactide fragment analog without hormonal activity at MC2R. Proposed mechanisms include elevation of BDNF and NGF in hippocampus and striatum (in animal models), modulation of dopamine metabolism, and neuroprotective effects via anti-apoptotic pathways. A clear primary receptor is not established.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studio sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Glepaglutide	Semax
Germania	Non approvato	Non approvato
RU	—	Su prescrizione
Stati Uniti	Non approvato	Non approvato

Voci complete

Frequently asked questions

What is the difference between Glepaglutide and Semax?: Glepaglutide is classified as "Ricerca (altro)", while Semax is classified as "Ricerca (altro)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Semax: Synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10). Approved in Russia for ischaemic stroke, cognitive function and ADHD in children. Western phase-3 trials absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Glepaglutide or Semax?: The highest available evidence level is "RCT sull'uomo" for Glepaglutide and "Studio sull'uomo" for Semax. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Glepaglutide and Semax in Germany and the United States?: Germania: Glepaglutide — Non approvato, Semax — Non approvato. Stati Uniti: Glepaglutide — Non approvato, Semax — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

Glepaglutide

Semax

Germania

Non approvato

—

Su prescrizione

Stati Uniti

Non approvato

Frequently asked questions

What is the difference between Glepaglutide and Semax?

Glepaglutide is classified as "Ricerca (altro)", while Semax is classified as "Ricerca (altro)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Semax: Synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10). Approved in Russia for ischaemic stroke, cognitive function and ADHD in children. Western phase-3 trials absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Glepaglutide or Semax?

The highest available evidence level is "RCT sull'uomo" for Glepaglutide and "Studio sull'uomo" for Semax. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Glepaglutide and Semax in Germany and the United States?

Germania: Glepaglutide — Non approvato, Semax — Non approvato. Stati Uniti: Glepaglutide — Non approvato, Semax — Non approvato. These are factual summaries with source and review date on the individual pages.